SCHEMBL2394396

SCHEMBL2394396

[c]1ncc2cocc2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3943498 0.67
SCHEMBL2640123 0.65
SCHEMBL17765443 0.64
SCHEMBL19307656 0.64
SCHEMBL2394507 0.64
SCHEMBL17713551 0.64
SCHEMBL5342100 0.62 MAPK13 (0.34)
SCHEMBL5337590 0.62 PDGFRB (0.32)
SCHEMBL17713556 0.62
SCHEMBL158440 0.62 KDM4E (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450320-B2 Hexahydropyrazinotriazinone derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2019-10-22 US claimed
US-20180362532-A1 Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-12-20 US claimed
EP-3386984-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-10-17 EP claimed
WO-2017097871-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2017-06-15 WO claimed
US-10450320-B2 Hexahydropyrazinotriazinone derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2019-10-22 US disclosed
US-20180362532-A1 Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-12-20 US disclosed
EP-3386984-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-10-17 EP disclosed
WO-2017097871-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2017-06-15 WO disclosed
EP-2719701-B1 Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides GILEAD SCIENCES INC (US) 2017-04-05 EP disclosed
EP-2719701-A1 methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides GILEAD SCIENCES, INC. (US) 2014-04-16 EP disclosed
EP-2396340-B1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2013-12-18 EP disclosed
EP-2411395-B1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2013-05-29 EP disclosed
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed
EP-2396340-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT Gilead Sciences, Inc. (US) 2011-12-21 EP disclosed
US-8012942-B2 Carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-09-06 US disclosed
WO-2010093608-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-19 WO disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
EP-1067123-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-01-10 EP disclosed